Close Menu

cytogenetics

NEW YORK (GenomeWeb) – PerkinElmer has decided to close its Signature Genomics cytogenetic testing services business.

NEW YORK (GenomeWeb) - While chromosomal microarray analysis has become the first-tier cytogenetic test for diagnosing individuals with constitutional abnormalities around the world, geneticists continue to struggle with a high level of findings of unknown significance.

Affymetrix has provided more information about how it achieved US Food and Drug Administration clearance for its CytoScan Dx Assay chromosomal microarray analysis offering.

Chromosomal microarray analysis may be widely regarded as a first-tier method for both pediatric and prenatal cytogenetic testing, but that hasn't convinced some insurers to reimburse such tests.

NEW YORK (GenomeWeb News) – Two forms of a rare subgroup of acute lymphoblastic leukemia form through chromothripsis, or catastrophic chromosome shattering, researchers from the Wellcome Trust S

The discovery of variants of unknown significance during a prenatal chromosomal microarray analysis can create headaches for genetic counselors who are used to delivering certain results to patients, according to the authors of a recent paper.

Oxford Gene Technology this week announced that it has acquired Cytocell, a supplier of probes for fluorescence in situ hybridization experiments.

NEW YORK (GenomeWeb News) – Oxford Gene Technology said today that it has acquired Cytocell for an undisclosed sum.

CombiMatrix has benefitted from new guidelines that recommend prenatal chromosomal microarray analysis as a first-line test in the case of abnormal ultrasound findings, as well as a preferred test to identify the cause of death in stillbirths.

Oxford Gene Technology announced this week that it has been awarded a tender by the UK National Health Service to supply chromosomal microarrays to four labs in Britain, with an additional eight labs able to procure arrays through an agreed-upon supply framework.

Pages

The Wall Street Journal reports that Russia's announcement of a coronavirus vaccine approval was met with concern as safety testing has not yet been completed.

New Scientist writes there aren't much data available on the accuracy of the two rapid COVID-19 tests the UK plans to roll out.

In PNAS this week: downstream effect of oncoprotein fusion, epigenetic changes influence tRNAs in colon cancer, and more.

Nature News reports that recent proposed changes to the US National Science Foundation have raised concerns about a shift away from the agency's focus on basic research.